VIR
Vir BiotechnologyCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The Q1 update materially strengthened the balance-sheet and execution narrative: the Astellas collaboration closed, management pointed to $315 million of collaboration-related cash not yet in the March 31 balance, runway was extended into the second half of 2028, and the company kept multiple 2026 data hooks across CHD and oncology [#8-K-2026-05-06] [#10-Q-2026-05-07].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.4.
What can break
Lead-program risk remains high because the biggest value inflection is still late-2026 ECLIPSE 1 topline in chronic hepatitis delta, with later ECLIPSE 2 and 3 data following in 2027 [#10-Q-2026-05-07].
Momentum
44
Value
41
Sentiment
70
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $10.50 · Bull $16.00 · Bear $6.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $20.78
Why
Momentum44 · Δ7d -0.2
Value41 · Δ7d +0.1
Sentiment70 · Δ7d +5.4
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
44
34% active weight
Current posture
7d trendImproving
Δ7d
-0.2
Δ21d
-37.5
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
70
33% active weight
Current posture
7d trendImproving
Δ7d
+5.4
Δ21d
+11.9
Why this grade
Composite grade C. Momentum 43.7 / Value 41.1 / Sentiment 69.6
Fundamentals (TTM)As of 2026-05-29
Fundamentals (TTM)
As of 2026-05-29
Market Cap
$1.61B
Beta
1.69
Shares Out
139.13M
P/E (TTM) · Derived
-3.7
P/S (TTM)
47.78
P/FCF (TTM) · Derived
-3.46
Rev YoY
-89.9%
EPS YoY
+24.9%
Gross Margin
+95.9%
Op Margin
-3253.6%
Net Debt
-$905.35M
Current Ratio
7.25
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology